Company news

Ligand Pharmaceuticals Incorporated news in 2025

Ligand Pharmaceuticals Incorporated's news releases, calls and decks from 2025, newest first.

View company

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

December 8, 2025

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

November 5, 2025

Ligand to Participate in November Investor Conferences

October 29, 2025

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

October 22, 2025

Ligand to Host Investor Day on December 9, 2025

October 15, 2025

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

October 8, 2025

Ligand to Participate in September Investor Conferences

August 18, 2025

Ligand Announces Closing of Convertible Senior Notes Offering

August 13, 2025

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

August 10, 2025

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

August 10, 2025

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

August 6, 2025

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

August 5, 2025

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

July 31, 2025

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

July 23, 2025

LGND Raises $9M to Make Earth Data Intuitive and Actionable

July 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 9, 2025

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

July 1, 2025

Ligand Announces 2025 Investor Day in New York City

June 10, 2025

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025

Ligand Reports First Quarter 2025 Financial Results

May 7, 2025

Ligand to Participate in May Investor Conferences

April 30, 2025

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

April 23, 2025

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

April 16, 2025

Ligand to Participate in March Investor Conferences

March 2, 2025

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

February 24, 2025

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

February 12, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025

Calls in 2025

Decks in 2025